ArticleEJHaem2026
Single-Agent Selinexor Versus Physician's Choice in Previously Treated Myelofibrosis: Results From the Phase 2 XPORT-035 Study.
Article in EJHaem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04562870 (A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician's Choice in Patients With Previously Treated Myelofibrosis
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Janus kinase inhibitors (JAKis), the current standard of care for myelofibrosis (MF), provide clinical benefit, but responses are frequently incomplete, non-durable, and associated with cytopenias, underscoring the need for therapies with novel mechanisms of action. Selinexor, an oral selective inhibitor of Exportin 1 (XPO1), modulates nuclear-cytoplasmic transport, inflammatory signaling, and cancer cell proliferation. Methods: XPORT-MF-035, a global, Phase 2, randomized, open-label study comparing selinexor monotherapy with physician's choice (PC) in MF previously treated with JAKi, randomized patients 1:1 to selinexor or PC, with crossover permitted upon disease progression or inadequate spleen response. Primary endpoint was spleen volume reduction ≥ 35% (SVR35). Additional endpoints included symptom improvement, hematologic outcomes, plasma cytokine analyses, and safety. Results: Twenty-four patients were enrolled and treated. In the efficacy-evaluable population, SVR35 at any time was achieved by 29% (2/7) and 13% (1/8) of selinexor- and PC-treated patients, respectively; 8% (1/12) in each arm achieved SVR35 at Week 24 in the intent-to-treat population. Among evaluable patients, 40% (2/5) achieved SVR35 following selinexor crossover. Symptom improvement was observed with selinexor but not PC. Selinexor-treated patients experienced fewer Grade ≥ 3 anemia events with lower transfusion burden and reductions in multiple proinflammatory cytokines. Selinexor was generally well tolerated; common treatment-emergent adverse events (TEAEs) included anemia, asthenia, and decreased weight. One TEAE leading to death occurred in the selinexor and two in PC; none were considered treatment-related. Conclusions: Despite limited sample size, XPORT-MF-035 provides descriptive data on the safety, tolerability, and biological activity of selinexor monotherapy in previously treated MF, supporting further evaluation in this population. Trial Registration: ClinicalTrials.gov identifier: NCT04562870.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.